In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


ThirdWave Pushes for Parity

Executive Summary

Third Wave Technologies wants its Invader technology to be as ubiquitous as PCR. Since a deal with potential buyer Applera fell through two years ago, the company has begun several high-profile collaborations, including one with the Japanese SNP initiative, which now accounts for 50% of revenues. Its efforts appear to be paying off, but the company is fighting an uphill battle in an intensely competitive field.

You may also be interested in...

A Genomics Tool Company's Transition From Research to the Clinic

The late 1990s genomics implosion spurred many genomics tools companies focusing on research laboratories to re-direct their attention to the clinic. The expectation was that innovative diagnostic tests and analytic platforms could do for them what collapsing research markets couldn't. Among those hit hard was Third Wave Technologies Inc., which was forced to re-evaluate its priorities and step up the pace of its commercialization timetable, while reducing emphasis on research. TWT's struggles are similar to those of other genomics companies facing the same tough environment, but its story is also universally applicable to medical device startups, which start with a strong scientific orientation and, often painfully, need to make business their major priority.

Chinese Companies Progress Peptide Fusion Inhibitors For COVID-19

China's Hybio, Youcare and Shanxi Jinbo appear to be the only three companies in the world trying to develop a fusion inhibitor for COVID-19, the most advanced of which has now moved into a domestic Phase II trial.


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts